Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC
Sponsor: European Institute of Oncology
Summary
This study will prospectively determine the feasibility and oncological safety of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in inflammatory breast cancer patients traditionally considered ineligible for SLNB due to locally advanced cancer with skin/chest wall involvement (cT4d) and heavy nodal burden at presentation (cN1/N2). This study will also assess the identification rate of sentinel lymph-node (SLN) (using single tracer mapping) after NACT in this patient population. Finally, the study will determine the long-term outcome of such cohort.
Official title: Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Inflammatory Breast Cancer: a Prospective Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2025-12-12
Completion Date
2030-08
Last Updated
2026-01-06
Healthy Volunteers
No
Interventions
SLN identification using technetium-99m
SLN Biopsy after pre-surgery positive SLN visualization.
SLN intra-operatory identification with radioguided surgery
SLN biopsy after no pre-surgery SLN visualization using technetium-99m and intra-surgery SLN identification.
Axillary Limph Node Dissection (ALND)
Axillary Limph Node Dissection (ALND) after no pre-surgery SLN visualization using technetium-99m and no intra-surgery SLN identification.
Locations (1)
European Institute of Oncology
Milan, Italy